Using Tocilizumab in Hematologic Malignant Patients with Severe COVID-19 Infection - Case Series Report
Description
CONCLUSION: Tocilizumab can improve the outcome of severe COVID-19 infection in hematologic malignancy patients with severe immunodeficiency without severe adverse reactions.
